Announcements

  • Special Issue on "Advances in Musculoskeletal and Neuromuscular Rehabilitation"

    17-11-2023
    Introduction

    Over the past few decades, significant progress has been made in both our scientific comprehension and therapeutic approaches concerning neuromuscular disorders (NMDs) and musculoskeletal disorders (MSDs). These advancements have considerably expanded our treatment options for conditions impacting the neuromuscular and musculoskeletal systems, reflecting an enduring commitment to enhancing outcomes and the quality of life for individuals suffering from these disorders.

    The special issue titled "Advances in Musculoskeletal and Neuromuscular Rehabilitation" offers a platform for disseminating the latest research and innovations in the dynamic fields of musculoskeletal and neuromuscular rehabilitation. Read more.

  • Equi E-News – your resource for the latest advances in Functional Electrical Stimulation (FES) and equine therapy

    26-10-2023


    Equi E-News is produced by EquiNew, a company dedicated to designing physical rehabilitation treatment equipment and protocols specifically for use with horses.

    FES Therapy Read how FES can help provide a supportive treatment to promote function recovery even after injury to a specific nerve.

    About EquiNew As the founder of the use of Functional Electrical Stimulation (FES) for equine therapy, Dr. Sheila Schils and EquiNew leads the world in providing an ideal treatment or muscle-based problems. The FES technology will reduce muscle spasms, atrophy and asymmetry, as well as improve vertebral and articular range of motion and help to re-educate muscle memory. The science supporting the application of FES to improve human muscles is decades old. EquiNew has also been shown to be helpful for equine muscle problems.

     

    For more information go to: https://mailchi.mp/5008d035ffbd/equinew-newsletter?e=%5BUNIQID%5D

     

  • Great News

    30-06-2023

    Clarivate today has just published the new edition of the Journal Citation ReportEuropean Journal of Translational Myology achieved an initial impact factor of 2.2! In the Clarivate’s “MEDICINE, RESEARCH & EXPERIMENTAL" category, EJTM ranks 130/189, Q3 percentile. 

    We would like to express our gratitude to everyone who contributed to the journal. Their continued trust and engagement have motivated us to strive for excellence and continue pushing the boundaries of research.

    As we celebrate this remarkable accomplishment, we remain committed to upholding the highest standards of academic publishing. We will continue to provide a platform for groundbreaking research and foster an environment that promotes collaboration and innovation. Together, we will continue to make significant contributions to the advancement of knowledge and the progress of our fields.

    We look forward to sharing more exciting developments and groundbreaking research with our audience in the future.